Descovy (emtricitabine;tenofovir alafenamide)
- Region
- 🇪🇺 EU
- Active substance
- emtricitabine;tenofovir alafenamide
- Company
- Gilead Sciences Ireland UC
- Status
- Authorised
- Therapeutic area
- HIV Infections
- CHMP opinion
- Thu 25 Feb 2016
- EU approval
- Thu 21 Apr 2016
- Application
- EMEA/H/C/004094
- ATC
- J05AR17
- Official record
- www.ema.europa.eu
Indication
Descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (HIV-1).
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Symtuza Authorised · Janssen-Cilag International
- 🇪🇺 Genvoya Authorised · Gilead Sciences Ireland UC
- 🇪🇺 Emtricitabine / Tenofovir alafenamide Viatris Authorised · Viatris Limited
- 🇪🇺 Biktarvy Authorised · Gilead Sciences Ireland UC
Follow Descovy
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.